Advertisement
Screener

Biomea Fusion, Inc. (BMEA) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Biomea Fusion, Inc. Stock-Based Compensation

Biomea Fusion, Inc. (BMEA) reported Stock-Based Compensation of $3.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-05

  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.59M, a 38.32% decline year-over-year.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.58M, a 50.08% decline year-over-year.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.84M, a 59.06% decline year-over-year.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.94M, a 59.09% decline year-over-year.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $9.52M, a 50.14% decline from fiscal 2024.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $19.09M, a 35.12% increase from fiscal 2023.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $14.13M, a 36.72% increase from fiscal 2022.
  • Biomea Fusion, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.34M, a 65.80% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$1.59M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$3.17M
10-Q · filed 2026-08-05
$5.01M
derived: sum of 3 quarters · filed 2026-08-05
$6.95M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$1.58M
10-Q · filed 2026-05-11
$3.42M
derived: sum of 2 quarters · filed 2026-05-11
$5.36M
derived: sum of 3 quarters · filed 2026-05-11
$7.93M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$1.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
$3.78M
derived: sum of 2 quarters · filed 2026-03-24
$6.35M
derived: sum of 3 quarters · filed 2026-08-05
$9.52M
10-K · filed 2026-03-24
2025-09-30$1.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$4.51M
derived: sum of 2 quarters · filed 2026-08-05
$7.68M
10-Q · filed 2025-11-04
$12.17M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$2.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$5.74M
10-Q · filed 2026-08-05
$10.23M
derived: sum of 3 quarters · filed 2026-08-05
$14.97M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$3.17M
10-Q · filed 2026-05-11
$7.66M
derived: sum of 2 quarters · filed 2026-05-11
$12.40M
derived: sum of 3 quarters · filed 2026-05-11
$17.24M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$4.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
$9.23M
derived: sum of 2 quarters · filed 2026-03-24
$14.07M
derived: sum of 3 quarters · filed 2026-03-24
$19.09M
10-K · filed 2026-03-24
2024-09-30$4.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$9.58M
derived: sum of 2 quarters · filed 2025-11-04
$14.60M
10-Q · filed 2025-11-04
$18.47M
derived: sum of 4 quarters · filed 2026-03-24
2024-06-30$4.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$9.86M
10-Q · filed 2025-08-05
$13.73M
derived: sum of 3 quarters · filed 2026-03-24
$17.32M
derived: sum of 4 quarters · filed 2026-03-24
2024-03-31$5.02M
10-Q · filed 2025-05-05
$8.89M
derived: sum of 2 quarters · filed 2026-03-24
$12.48M
derived: sum of 3 quarters · filed 2026-03-24
$15.92M
derived: sum of 4 quarters · filed 2026-03-24
2023-12-31$3.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24
$7.46M
derived: sum of 2 quarters · filed 2026-03-24
$10.90M
derived: sum of 3 quarters · filed 2026-03-24
$14.13M
10-K · filed 2026-03-24
2023-09-30$3.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29
$7.03M
derived: sum of 2 quarters · filed 2024-10-29
$10.27M
10-Q · filed 2024-10-29
$12.98M
derived: sum of 4 quarters · filed 2025-03-31
2023-06-30$3.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31
$6.67M
10-Q · filed 2024-07-31
$9.38M
derived: sum of 3 quarters · filed 2025-03-31
$12.12M
derived: sum of 4 quarters · filed 2025-03-31
2023-03-31$3.23M
10-Q · filed 2024-05-02
$5.95M
derived: sum of 2 quarters · filed 2025-03-31
$8.68M
derived: sum of 3 quarters · filed 2025-03-31
$11.24M
derived: sum of 4 quarters · filed 2025-03-31
2022-12-31$2.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$5.45M
derived: sum of 2 quarters · filed 2025-03-31
$8.01M
derived: sum of 3 quarters · filed 2025-03-31
$10.34M
10-K · filed 2025-03-31
2022-09-30$2.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30
$5.29M
derived: sum of 2 quarters · filed 2023-10-30
$7.62M
10-Q · filed 2023-10-30
$9.55M
derived: sum of 4 quarters · filed 2024-03-28
2022-06-30$2.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31
$4.89M
10-Q · filed 2023-07-31
$6.82M
derived: sum of 3 quarters · filed 2024-03-28
$8.74M
derived: sum of 4 quarters · filed 2024-03-28
2022-03-31$2.33M
10-Q · filed 2023-05-02
$4.26M
derived: sum of 2 quarters · filed 2024-03-28
$6.18M
derived: sum of 3 quarters · filed 2024-03-28
$7.64M
derived: sum of 4 quarters · filed 2024-03-28
2021-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$3.85M
derived: sum of 2 quarters · filed 2024-03-28
$5.32M
derived: sum of 3 quarters · filed 2024-03-28
$6.23M
10-K · filed 2024-03-28
2021-09-30$1.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$3.38M
derived: sum of 2 quarters · filed 2022-11-07
$4.30M
10-Q · filed 2022-11-07
2021-06-30$1.46M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01
$2.38M
10-Q · filed 2022-08-01
2021-03-31$919.00K
10-Q · filed 2022-05-16
2020-12-31$322.00K
10-K · filed 2023-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Equillium, Inc. (EQ)United States$0.109B-11.27
GENELUX Corp (GNLX)United States$0.110B-3.83
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
ProMIS Neurosciences Inc. (PMN)$0.102B
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Anixa Biosciences Inc (ANIX)United States$0.096B